CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services, a leading drug development organization specializing in the 505(b)(2) approval pathway, strengthens its leadership and expertise in pharmaceutics with the addition of Olu Aloba, Ph.D., to the team as senior director of pharmaceutics.
In his new role, Aloba will provide Camargo's clients with pharmaceutical development and regulatory consulting with special emphasis on the 505(b)(2) pathway and will direct chemistry, manufacturing and control (CMC) aspects of drug and device development activities. His responsibilities will include communicating with regulatory agencies regarding CMC issues, serving as senior technical advisor on all drug and device initiatives and overseeing technical research policies at Camargo.
A subject matter expert in pharmaceutical development, Aloba brings more than 20 years of industry experience in research and development, technology transfers, strategic and operational direction and regulatory submissions. His pharmaceutical expertise includes dosage form design, quality by design (QbD) formulation and process development.
"Olu's history as a pharmacist and his accomplishments in product development and approval success will prove beneficial to our clients," said Ken Phelps, Camargo president and CEO. "His leadership and management experience make him an important element in the company's growth."
Prior to joining Camargo, Aloba was director of pharmaceutical development at Warner Chilcott where he directed in-house and outsourced QbD development as well as technology transfers and manufacturing processes.
Aloba's professional accomplishments include leading teams through numerous women's health care and dermatology product approvals, as well as developing a patented formulation for a hormone replacement product line.
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is your full-service drug development partner specializing in the 505(b)(2) process. Before development even begins, we verify profit potential by working with your team to develop a comprehensive program and timeline complete with important milestones and cost objectives. We manage every facet of the plan throughout your development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission. Connect with Camargo on LinkedIn, the President's blog or visit www.camargopharma.com for more information.
For Camargo Pharmaceutical Services
Lea Studer, 308-237-5567